Company intelligence / Profile preview

PSYCH

London, United Kingdom

Ownership: Private
Development stage: Other

Overview

PSYCH is a leading media and data platform dedicated to the psychedelic medicine industry, providing market intelligence, industry news, and high-level networking opportunities. The company produces the annual PSYCH Symposium and publishes the influential 'Psychedelics as Medicine Report,' which offers comprehensive data on the sector's clinical and commercial landscape. Acquired by Psych Capital in 2022, PSYCH serves as a central hub for investors, researchers, and healthcare professionals navigating the emerging field of psychedelic-assisted therapies. Its services include data-driven insights, strategic consulting, and a digital platform that tracks the progress of psychedelic drug development and regulatory shifts.

Therapeutic areas: Psychiatry
Industry: Biomedical IT and Biomedical Data Platforms

Partnerships

Aquis Stock ExchangeBlossomMicrodose

Beyond the preview

Go deeper on PSYCH.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PSYCH.

Explore the full profile